Paroxysmal Nocturnal Hemoglobinuria Treatment Market Trends

Ongoing innovation in the development of targeted therapies, such as complement inhibitors like eculizumab and ravulizumab, has revolutionized PNH treatment. These therapies effectively reduce hemolysis and improve patient outcomes, leading to higher adoption rates, which are anticipated to propel market growth. Moreover, leading pharmaceutical companies are heavily investing in the research and development of new drugs and therapies for PNH, resulting in a robust pipeline of potential treatments that contribute to market growth. For instance, in April 2024, Voydeya (danicopan) was approved in the U.S. as an add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with PNH. This approval aims to broaden treatment availability, complementing existing therapies for PNH and contributing to market growth.